Breaking

AI Eating Itself: How AI Companies Use Their Own Tools to Cut Costs ● The Skills Gap Widening: Why AI Specialists Thrive While Adjacent Roles Disappear ● Q1 2026 Layoff Deep Dive: 39,000+ Jobs Cut in Just 3 Months ● The Great AI Consolidation: How Tech Giants Are Centralizing AI Development ● The Global AI Job Divide: How Emerging Markets Are Getting Left Behind ● The Skills Gap Paradox: Why Companies Buy AI Tools But Can't Teach Workers to Use Them ● The Great Skills Gap: Why Workers Are Falling Behind in the AI Era ● This Week in AI Layoffs: The Numbers, the Narrative, and What Comes Next ● AI Triggers Mass Layoffs in 2026? Future of Tech Jobs Explained ● Big Tech companies are now racing to see who can build the best AI coworker - Sherwood NewsAI Eating Itself: How AI Companies Use Their Own Tools to Cut Costs ● The Skills Gap Widening: Why AI Specialists Thrive While Adjacent Roles Disappear ● Q1 2026 Layoff Deep Dive: 39,000+ Jobs Cut in Just 3 Months ● The Great AI Consolidation: How Tech Giants Are Centralizing AI Development ● The Global AI Job Divide: How Emerging Markets Are Getting Left Behind ● The Skills Gap Paradox: Why Companies Buy AI Tools But Can't Teach Workers to Use Them ● The Great Skills Gap: Why Workers Are Falling Behind in the AI Era ● This Week in AI Layoffs: The Numbers, the Narrative, and What Comes Next ● AI Triggers Mass Layoffs in 2026? Future of Tech Jobs Explained ● Big Tech companies are now racing to see who can build the best AI coworker - Sherwood News

Curated from External Source

stocktitan.netWednesday, March 4, 20264 min read

Curated and analyzed by the JobGoneToAI team. Original reporting by stocktitan.net.

Theravance Biopharma Cuts Workforce by 50% Following Failed Drug Trial

BreakingHotnegative sentiment

Failed rare-disease trial pushes Theravance to slash jobs and eye a sale

— stocktitan.net

Key Takeaway

Theravance Biopharma is undergoing a significant workforce reduction of approximately 50% due to the failure of its Phase 3 CYPRESS study for ampreloxetine. The company is restructuring to cut operating expenses and is considering a potential sale.

From the Original Report

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions Rhea-AI Impact (High) Rhea-AI Sentiment (Neutral) Tags clinical trial Rhea-AI Summary English Arabic French German Italian Korean Spanish Theravance Biopharma (NASDAQ: TBPH) reported that the

Phase 3 CYPRESS study of ampreloxetine did not meet the primary OHSA composite endpoint, and the company will wind down the program. The Board's Strategic Review Committee is accelerating a review of alternatives, including a potential sale.

The company is restructuring to cut operating expenses ~60% (≈$70M run-rate), expect ~50% workforce reduction, and forecasts $60–$70M annualized cash flow starting Q3 2026. Cash was $326.5M at 12/31/2025; approximately $400M expected EoQ1 2026, and a $100M TRELEGY milestone is expected in 2026. Loading... Loading translation...

This is an excerpt. Read the full article at stocktitan.net.

Original Source

Read original reporting at stocktitan.net

JobGoneToAI curates, verifies, and adds original analysis to third-party reporting. We link to the original source so you can verify the facts yourself.

job lossrestructuringbiopharma

Theravance Biopharma Cuts Workforce by 50% Following Failed Drug Trial

Key Takeaway

From the Original Report

Related Stories

Block Announces 40% Workforce Reduction Amid AI Focus and Restructuring

Amazon Announces 16,000 Job Cuts Amid AI-Driven Cloud Strategy

Nordea to Cut 1,500 Jobs Due to AI-Driven Restructuring